Key result
Higher glycemic variability, evaluated by mean amplitude of glycemic excursions (MAGE), was an independent risk factor for diabetic peripheral neuropathy in patients with well-controlled type 2 diabetes.
Why the study?
Is glycemic variability associated with diabetic peripheral neuropathy in type 2 diabetes patients with well-controlled HbA1c?
Case-Control (n=90)
No
Is glycemic variability associated with diabetic peripheral neuropathy in type 2 diabetes patients with well-controlled HbA1c?
Glycemic variability, specifically mean amplitude of glycemic excursions (MAGE), is an independent risk factor for diabetic peripheral neuropathy in type 2 diabetes patients even when HbA1c is well-controlled.
Answers are grounded in this paper and cite their sources.
May warrant glycemic variability monitoring in well-controlled type 2 diabetes; hypothesis-generating and requires prospective validation.
BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common microvascular complications of diabetes. Glycemic variability could be an independent risk factor for diabetes complications in addition to average glucose. Type 2 diabetes with well-controlled glycosylated hemoglobin A1c (HbA1c) may have different terms of glycemic variability and vascular complication consequences. The aim of the study is to investigate the relationship between glycemic variability and DPN in type 2 diabetes with well-controlled HbA1c (HbA1c < 7.0%). METHODS: 45 type 2 diabetes with well-controlled HbA1c(HbA1c < 7.0%) and with DPN (DM/DPN group) were recruited in the study, and 45 type 2 diabetes with well-controlled HbA1c and without DPN (DM/-DPN group) were set as controls. The two groups were also matched for age and diabetic duration. Blood pressure, body mass index(BMI), insulin sensitivity index (Matsuda index, ISI), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDLC), and low density lipoprotein cholesterol (LDLC) were tested in the two groups. And all patients were monitored using the continuous glucose monitoring (CGM) system for consecutive 72 hours. The multiple parameters of glycemic variability included the standard deviation of blood glucose (SDBG), mean of daily differences (MODD) and mean amplitude of glycemic excursions (MAGE). RESULTS: The DM/DPN group had a greater SDBG, MODD and MAGE, when compared to the DM/-DPN group (p < 0.05). BMI, TC, and LDLC of DM/DPN group were lower than those of DM/-DPN group (p < 0.05). The patients with hypoglycemia were comparable between the two groups (p > 0.05). Univariate analysis showed DPN was closely associated with BMI (OR 0.82, CI 0.72-0.94, p = 0.005), TC (OR 0.63, CI 0.42-0.93, p = 0.02), LDLC (OR 0.4, CI 0.20-0.80, p = 0.009), SDBG (OR 2.95, CI 1.55-5.61, p = 0.001), MODD (OR 4.38, CI 1.48-12.93, p = 0.008), MAGE (OR 2.18, CI 1.47-3.24, p < 0.001). Multivariate logistic regression analysis showed that MAGE (OR 2.05, CI 1.36-3.09, p = 0.001) and BMI (OR 0.85, CI 0.73-0.99, p = 0.033) were significantly correlating with DPN. Glycemic variability, evaluated by MAGE, was the most significantly independent risk factor for DPN. CONCLUSIONS: There was a close relationship between glycemic variability evaluated by MAGE and DPN in type 2 diabetes with well-controlled HbA1c.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2014) conducted a case-control in Type 2 diabetes with well-controlled HbA1c (n=90). Glycemic variability (MAGE) vs. Lower glycemic variability was evaluated on Diabetic peripheral neuropathy (OR 2.05, 95% CI 1.36-3.09, p=0.001). Higher glycemic variability, evaluated by mean amplitude of glycemic excursions (MAGE), was an independent risk factor for diabetic peripheral neuropathy in patients with well-controlled type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: